Skip to main content

Table 1 Demographic characteristics of patients with CHC in Taiwan, 2001–2013

From: Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan

Variables

Total N = 13,203

CHC treated by PEG IFN/RB N = 3810

CHC nontreated N = 9393

P-value

n (%)

n (%)

n (%)

Age (years)

0.69

  < 20

612 (4.6)

183 (4.8)

429 (4.6)

 21–30

2104 (15.9)

610 (16.0)

1494 (15.9)

 31–40

2607 (19.7)

723 (19.0)

1884 (20.1)

 41–50

2430 (18.4)

704 (18.5)

1726 (18.4)

  > 51

5450 (41.3)

1590 (41.7)

3860 (41.1)

Sex

0.84

 Female

6733 (51.0)

1980 (52.0)

4753 (50.6)

 Male

6470 (49.0)

1830 (48.0)

4640 (49.4)

Region of residence

0.03

 Northern

3549 (26.9)

948 (24.9)

2601 (27.7)

 Central

3772 (28.6)

1149 (30.2)

2623 (27.9)

 Southern

5019 (38.0)

1450 (38.1)

3569 (38)

 Eastern

863 (6.5)

263 (6.9)

600 (6.4)

Diagnosed with TD

< 0.001

 Yes

417 (3.2)

173 (4.5)

244 (2.6)

 No

12,786 (96.8)

3637 (95.5)

9149 (97.4)

Past history

 Hypertension

< 0.001

  Yes

6908 (52.3)

1759 (46.2)

5149 (54.8)

  No

6295 (47.7)

2051 (53.8)

4244 (45.2)

 Hyperlipidemia

0.901

  Yes

4642 (35.2)

1383 (36.3)

3259 (34.7)

  No

8561 (64.8)

2427 (63.7)

6134 (65.3)

 Diabetes mellitus

< 0.001

  Yes

4282 (32.4)

1164 (30.6)

3118 (33.2)

  No

8921 (67.6)

2646 (69.4)

6275 (66.8)

 Liver cirrhosis

0.003

  Yes

2916 (22.1)

756 (19.8)

2160 (23.0)

  No

10,287 (77.9)

3054 (80.2)

7233 (77.0)

 CKD

< 0.001

  Yes

2473 (18.7)

552 (14.5)

1921 (20.5)

  No

10,730 (81.3)

3258 (85.5)

7472 (79.5)

 Goiter

0.48

  Yes

485 (3.7)

133 (3.5)

352 (3.7)

  No

12,718 (96.3)

3677 (96.5)

9041 (96.3)

  1. CHC chronic hepatitis C, TD thyroid dysfunction, CKD chronic kidney disease, PEG-IFN/RBV pegylated interferon/ribavirin